<DOC>
	<DOCNO>NCT01018732</DOCNO>
	<brief_summary>The primary objective evaluate persistence bactericidal antibodies adolescent subject complete study V59P6 receive either Novartis Meningococcal ( MenACWY ) Conjugate Vaccine Licensed polysaccharide Men ACWY vaccine ( Menomune® ) . The study also enroll age-matched subject never receive meningococcal vaccine ( naïve subject ) serve additional control group .</brief_summary>
	<brief_title>A Study Evaluate Persistence Immune Response Booster Dose MenACWY</brief_title>
	<detailed_description>Persistence antibody response 5 year one dose MenACWY Menomune</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy adolescent adult ( age 1623 year inclusive ) , either previously enrol parent study naïve meningococcal vaccination . Female subject negative pregnancy History meningococcal disease Receipt meningococcal vaccine outside parent study ( V59P6 ) Serious , acute , chronic illness include HIV infection/disease malignancy receipt vaccine 14 day prior study , expect duration study condition eye investigator would pose health risk subject render inappropriate research study</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Meningococcal</keyword>
	<keyword>ACWY</keyword>
	<keyword>Conjugate Vaccine</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Adolescents</keyword>
	<keyword>Persistence</keyword>
</DOC>